Trial · NCT02205762
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762, Phase 2, Phase 3, Active not recruiting, North American Consortium for Histiocytosis
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis. Trials, record NCT02205762. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02205762
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT number
- NCT02205762
- Status
- Active not recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 1,400 participants, actual
- Lead sponsor
- North American Consortium for Histiocytosis
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
- First posted
- 2014-07-31
- Last updated
- 2026-11-10
- Other registries' IDs
- eudract:2011-001699-20
Source ClinicalTrials.gov
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients with Reactivation Free Survival | 12 Months | Stratum I, II, VI |
| Primary | Response Rate of Second Cycle | 9 weeks | Stratum III |
| Primary | Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT) | 3 Years | Stratum IV |
| Primary | The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions | 2 Years | Stratum V |
| Primary | The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH | 2 Years | Stratum V |
| Primary | Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc. | 2 Years | From all treatment stratum via long-term follow up in Stratum VII |
| Secondary | Overall Survival | 2 Years | Stratum I |
| Secondary | Number of Participants with Serious and Non-Serious Adverse Events | 2 Years | |
| Secondary | Incidence of Permanent Consequences | 2 Years | All Stratum |
| Secondary | Cumulative incidence of reactivations in risk organs | 2 Years |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02205762
GET https://conductscience.org/api/trials/v1/NCT02205762/registered?page=2